Association of killer cell immunoglobulin–like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus

Abstract

To determine whether killer cell immunologlobulin–like receptor (KIR) genotypes are associated with vasculitis, vascular arterial events or anticardiolipin (aCL) antibodies in patients with lupus. A total of 304 patients followed prospectively at the University of Toronto Lupus Clinic were assessed for the occurrence of vasculitis and vascular arterial events. Molecular HLA-C and KIR (presence or absence of KIR2DL1, 2DL2, 2DL3, 2DS1 and 2DS2) genotyping were performed. Chi-square and logistic regression were used to analyse association between KIR genes and vascular arterial events and aCL antibodies. In patients with vascular arterial events, there was a significant increase in KIR2DS2 (60% vs 45%, P = 0.02) and in KIR2DL2 (62% vs 47%, P = 0.01) compared with patients without events. There was no increase in activating KIR genotypes in patients with vasculitis. In patients with aCL antibodies, significant increases were seen in KIR2DS2 (54% vs 41%, P = 0.03) and KIR2DL2 (58% vs 41%, P = 0.003), but KIR2DL3 was decreased (87% vs 95%, P = 0.03). Logistic regression confirmed independent association of KIR2DS2 with vascular arterial events. We found an increase in KIR2DS2 in lupus patients with vascular arterial events, but not in patients with vasculitis.

Keywords

genetic associations KIR genes systemic lupus erythematosus vascular arterial events

Get full access to this article

View all access options for this article.

References

1 Alarcon-Segovia D Alarcon-Riquelme M . Etiopathogenesis of systemic lupus erythematosus. In: Lahita, RG, (ed), Systemic lupus erythematosus. Academic Press; 2004. p. 93–107.

2 Gladman DD Urowitz MB . In: Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds), Rheumatology. Mosby, St. Louis Mo, USA; 2003. p. 1359–1379.

3 Nikpour M Urowitz MB Gladman DD . Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329–354.

4 Weyand CM Goronzy JJ Liuzzo G . T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001; 76: 1011–1020.

5 Williams AP Bateman AR Khakoo SI . Hanging in the balance. KIR and their role in disease. Mol Interv 2005; 5: 226–240.

6 Yen JH Moore BE Nakajima T . Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159–1167.

7 Pellett F Siannis F Vukin I Lee P Urowitz M Gladman D . Are KIRs associated with autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007; 69(Suppl. 1): 106–108.

8 Urowitz MB Gladman DD . Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto lupus clinic experience. Rheum Dis Clin North Am 2005; 31: 211–221.

9 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

10.

10 Hochberg MC . Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

11.

11 Gladman DD Ibanez D Urowitz MB . Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

12.

12 Gladman D Ginzler E Goldsmith C . The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.

13.

13 Martin MP Nelson G Lee JH . Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169: 2818–2822.

14.

14 Bruce IN Urowitz MB Gladman DD Ibanez D Steiner G . Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum 2003; 48: 3159–3167.

15.

15 Hallenbeck JM Hansson GK Becker KJ . Immunology of ischemic vascular disease: plaque to attack. Trends Immunol 2005; 26: 550–556.

16.

16 Liuzzo G Giubilato G Pinnelli M . T cells and cytokines in atherogenesis. Lupus 2005; 14: 732–735.

17.

17 Esdaile JM Abrahamowicz M Grodzicky T . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2215–2217.

18.

18 Rahman P Urowitz MB Gladman DD Bruce IN Genest J . Contribution of traditional risk factors to coronary artery disease in patients with SLE. J Rheumatol 1999; 26: 2363–2368.

19.

19 Hsu KC Chida S Geraghty DE Dupont B . The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 2002; 190: 40–52.

20.

20 Urowitz MB Ibanez D Gladman DD . Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007; 34: 70–75.

21.

21 Brey RL Abbott RD Curb JD . Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001; 32: 1701–1706.

22.

22 Vaarala O . Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 2(Suppl. 7): S132–S134.

23.

23 Lopez LR Dier KJ Lopez D Merrill JT Fink CA . Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121: 142–149.

24.

24 Mizutani H Kurata Y Kosugi S . Monoclonal anticardiolipin autoantibodies established from the (New Zealand white x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995; 38: 1382–1388.

25.

25 Wu R Svenungsson E Gunnarsson I . Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin Exp Immunol 1999; 115: 561–566.

26.

26 Chung CP Oeser A Avalos I . Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8: R186.